<DOC>
	<DOC>NCT00635765</DOC>
	<brief_summary>The purpose of this study is to assess the safety profile of C2L-OCT-01 PR for up to an additional 96-week period in acromegalic patients who completed the C2L-OCT-01 PR-301 study.</brief_summary>
	<brief_title>Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<criteria>â€¢Subjects who have completed the 24week C2LOCT01 PR301 study Women of childbearing potential who are not taking adequate contraception or who are pregnant or lactating Subjects who have experienced any clinically significant adverse event related to study medication in C2LOCT01 PR301 study Subjects with uncontrolled Diabetes type II Subjects with signs or symptoms related to a tumor compression of the optical chiasm Subjects with symptomatic cholelithiasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Acromegaly</keyword>
</DOC>